Welcome to our dedicated page for Edesa Biotech SEC filings (Ticker: EDSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Edesa Biotech, Inc. (Nasdaq: EDSA) SEC filings page compiles the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical issuer focused on immuno-inflammatory diseases, Edesa uses its SEC reports to provide detail on clinical programs, funding agreements and capital markets activity related to its Medical Dermatology and Respiratory pipelines.
Investors can review current reports on Form 8-K that discuss material events such as positive Phase 3 results for paridiprubart (EB05) in Acute Respiratory Distress Syndrome (ARDS), amendments to a multi-year contribution agreement with the Government of Canada’s Strategic Innovation Fund, and updates to at-the-market equity offering programs. Other 8-K filings reference earnings releases for fiscal periods, giving context on operating expenses, research and development spending, and cash resources supporting programs like EB06 for vitiligo and EB01 for Allergic Contact Dermatitis.
Through its shelf registration statements and prospectus supplements, Edesa documents how it raises capital via at-the-market offerings and private placements of preferred and common shares. These filings outline the structure and size of offerings, use of proceeds for advancing EB06 into Phase 2 studies, and the terms under which additional common shares may be issued. Contribution agreements and amendments filed or referenced in periodic reports describe partially repayable government funding for EB05 clinical trials, regulatory submissions and non-clinical safety studies.
On Stock Titan, users can access Edesa’s SEC filings as they are made available from EDGAR and benefit from AI-powered summaries that highlight the key points in lengthy documents such as annual reports (Form 10-K), quarterly reports (Form 10-Q) and material 8-Ks. These tools help clarify disclosures on clinical milestones, financial obligations, government funding arrangements and equity issuance, and can also surface insider and governance-related filings such as Forms 3, 4 and 5 when they are filed. This page is a resource for analyzing how Edesa reports its progress, risks and capital structure in connection with its dermatology and respiratory drug candidates.
Edesa Biotech, Inc.’s Chief Executive Officer Pardeep Nijhawan reported multiple recent transactions in the company’s common shares. He received a grant of 10,016 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan, at a stated price of $0.00 per share.
He also bought 20,571 common shares in open-market transactions at a weighted average price of $1.5789 per share and 30,000 common shares at a weighted average price of $2.2232 per share, including purchases held through Pardeep Nijhawan Medicine Professional Corporation. Additional share holdings are reported indirectly through The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech Chief Executive Officer Pardeep Nijhawan reported an equity compensation grant on common shares. On February 19, 2026, he acquired 82,236 restricted share units, which vested in full upon grant under Edesa’s 2019 Equity Incentive Compensation Plan, at a reported price of $0.00 per share. These RSUs were received in lieu of a portion of his cash bonus for the calendar year ending December 31, 2025. Following this award, Nijhawan directly owns 595,226 common shares, and additional common shares are held indirectly through entities such as Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech reported additional positive Phase 3 results for its anti-TLR4 antibody paridiprubart in a 278-patient study. Across the full population, paridiprubart cut adjusted 28-day mortality to 24% versus 33% on placebo, a 27% relative risk reduction with strong statistical significance (p<0.001).
In a milder, 174-patient non-IMV subgroup, paridiprubart plus standard of care reduced adjusted 28-day mortality to 15% from 23%, a 35% relative risk reduction (p<0.005). Patients on paridiprubart also showed higher rates of clinical improvement by Day 28, and safety, adverse events and discontinuations were low and similar to placebo.
More than 400 patients have now received paridiprubart. Based partly on these results, Edesa has filed U.S. provisional patents covering use of paridiprubart in sepsis, acute kidney injury and pneumonia, adding to core composition-of-matter patents that extend into the 2030s. The drug is also being tested in a separate, government-funded ARDS study with enrollment of about 200 subjects for the company cohort.
Nantahala Capital Management and its principals reported a significant ownership position in Edesa Biotech. As of December 31, 2025, they may be deemed to beneficially own 855,583 common shares, representing 9.99% of the outstanding class. This total includes 230,583 shares that can be acquired within sixty days through convertible securities. Voting and dispositive power over all reported shares is shared among Nantahala, Wilmot B. Harkey, and Daniel Mack, with no sole authority. They certify the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Edesa Biotech.
Edesa Biotech, Inc. reported a net loss of $2.25 million for the quarter ended December 31, 2025, compared with a $1.62 million loss a year earlier. Research and development expenses rose to $1.12 million and general and administrative costs to $1.22 million, reflecting higher clinical and corporate activity.
The company ended the quarter with $12.1 million in cash and cash equivalents and working capital of $12.0 million, helped by $3.50 million of common share sales under its at-the-market program. Management cautions that there is a material uncertainty that may cast substantial doubt on its ability to continue as a going concern without additional funding.
Edesa is advancing EB06 for vitiligo toward a Phase 2 study and evaluating Phase 3 data for EB05 (paridiprubart) in acute respiratory distress syndrome, supported in part by up to C$23 million of Canadian government Strategic Response Fund backing.
Edesa Biotech, Inc. reported fiscal first quarter 2026 results and highlighted progress in its dermatology and respiratory drug programs. The company is manufacturing EB06, an anti-CXCL10 antibody, and placebo for a planned Phase 2 vitiligo study, with recruitment anticipated midyear 2026, subject to regulatory approvals. Edesa is also analyzing subgroup data and preparing conference presentations following positive Phase 3 results for paridiprubart in Acute Respiratory Distress Syndrome.
Total operating expenses rose to $2.3 million from $1.9 million a year earlier, driven by higher manufacturing-related R&D and increased noncash share-based compensation. Research and development expenses were $1.1 million, while general and administrative expenses were $1.2 million. Total other income declined to $0.1 million from $0.3 million due mainly to lower Canadian government reimbursement funding.
Edesa reported a net loss of $2.2 million, or $0.28 per share, for the quarter ended December 31, 2025, compared with a net loss of $1.6 million, or $0.48 per share, in the prior-year quarter. Cash and cash equivalents were $12.1 million and working capital was $12.0 million at December 31, 2025, supported by $3.4 million in net cash provided by financing activities during the quarter.
Edesa Biotech, Inc. insider Pardeep Nijhawan, who serves as Chief Executive Officer, director, and a 10% owner, reported an equity award in the company’s common shares. On 02/02/2026, he received 11,168 restricted share units that vested in full upon grant under the 2019 Equity Incentive Compensation Plan.
Following this grant, Nijhawan is shown with 512,990 common shares held directly. Additional common shares are reported as held indirectly through entities associated with him, including Pardeep Nijhawan Medicine Professional Corporation, The New Nijhawan Family Trust 2015, The Digestive Health Clinic Inc., and 1968160 Ontario Inc., with beneficial ownership disclaimed except to the extent of his pecuniary interest.
Edesa Biotech, Inc. reported that on December 12, 2025 it filed a prospectus supplement to increase to $2,262,508 the maximum aggregate amount of common shares that may be issued under its at-the-market offering agreement with H.C. Wainwright & Co.
The company disclosed that it has previously sold an aggregate of $3,718,324.61 of common shares under a prior prospectus supplement and $837,134 under a 2024 prospectus supplement for the same registration statement. The report also notes that Fasken Martineau DuMoulin LLP provided a legal opinion on the validity of the shares covered and clarifies that this disclosure does not itself constitute an offer to sell these securities.
The company whose common shares trade on Nasdaq under the symbol EDSA is updating its at-the-market offering so it may sell up to $2,262,508 of common shares from time to time through H.C. Wainwright & Co. as sales agent. This amount reflects the limits of General Instruction I.B.6 of Form S-3, which caps annual sales at one-third of public float for issuers with less than $75,000,000 held by non-affiliates. As of October 24, 2025, the public float was $19,273,618, based on 7,034,167 common shares held by non-affiliates at $2.74 per share. During the 12 months prior to this supplement, the company sold $4,162,030.62 of its securities under this rule, including $3,718,324.61 under the prior prospectus and $837,134 under an earlier prospectus supplement.
Edesa Biotech, Inc. files its annual report describing a biopharmaceutical company focused on inflammatory and immune-related diseases. Its lead respiratory candidate EB05 (paridiprubart) showed positive Phase 3 results in acute respiratory distress syndrome, with 28-day mortality of 39% on EB05 plus standard of care versus 52% on placebo, an absolute survival improvement of 13%, and a similar 13% benefit at 60 days, alongside a generally well-tolerated safety profile. EB05 is also being studied in a U.S. government-funded Phase 2 platform trial and backed by a Canadian Strategic Innovation Fund commitment of up to C$23 million, including up to C$5.75 million that is not repayable.
In medical dermatology, Edesa is advancing EB06, an anti-CXCL10 antibody for vitiligo, toward a Phase 2 trial in approximately 150 patients and is seeking partners for EB01, a Phase 3-ready topical therapy for allergic contact dermatitis. As of March 31, 2025, nonaffiliates held 5,728,786 of 7,022,678 common shares, with an aggregate market value of $13,978,238, and 8,333,823 common shares were outstanding as of December 12, 2025.